clofarabine has been researched along with Chronic Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Ollendorf, DA; Pearson, SD; Tice, JA; Whittington, MD | 1 |
| Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR | 1 |
2 trial(s) available for clofarabine and Chronic Disease
| Article | Year |
|---|---|
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning | 2016 |
1 other study(ies) available for clofarabine and Chronic Disease
| Article | Year |
|---|---|
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Chronic Disease; Clofarabine; Cost-Benefit Analysis; Humans; Immunotherapy, Adoptive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality-Adjusted Life Years; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Recurrence; Treatment Outcome; Young Adult | 2018 |